2. Academic Validation
  3. Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling

Epigenetic silencing of JAM3 promotes esophageal cancer development by activating Wnt signaling

  • Clin Epigenetics. 2022 Dec 2;14(1):164. doi: 10.1186/s13148-022-01388-3.
Weili Yang # 1,  Chao Guo # 2,  James G Herman 3,  Cheng Zhu 1 4,  Honghui Lv 1,  Xiaomo Su 1,  Lirong Zhang 5,  Meiying Zhang 6,  Mingzhou Guo 7 8
Affiliations

Affiliations

  • 1 Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing, 100853, China.
  • 2 Laboratory Animal Center, Chinese PLA General Hospital, #28 Fuxing Road, Beijing, 100853, China.
  • 3 The Hillman Cancer Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA, 15213, USA.
  • 4 Medical College of NanKai University, Tianjin, 300071, China.
  • 5 Henan Key Laboratory for Esophageal Cancer Research, Zhengzhou University, 40 Daxue Road, Zhengzhou, 450052, Henan, China.
  • 6 Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing, 100853, China. [email protected].
  • 7 Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, #28 Fuxing Road, Beijing, 100853, China. [email protected].
  • 8 Henan Key Laboratory for Esophageal Cancer Research, Zhengzhou University, 40 Daxue Road, Zhengzhou, 450052, Henan, China. [email protected].
  • # Contributed equally.
PMID: 36461092 DOI: 10.1186/s13148-022-01388-3
Abstract

Background: The role of JAM3 in different tumors is controversial. The epigenetic regulation and the mechanism of JAM3 remain to be elucidated in human esophageal Cancer (EC).

Methods: Eleven EC cell lines, 49 cases of esophageal intraepithelial neoplasia (EIN) and 760 cases of primary EC samples were employed. Methylation-specific polymerase chain reaction, immunohistochemistry, MTT, western blot and xenograft mouse models were applied in this study.

Results: The inverse association between RNA expression and promoter region methylation of JAM3 was found by analyzing 185 cases of EC samples extracted from the TCGA database (p < 0.05). JAM3 was highly expressed in KYSE450, KYSE520, TE1 and YES2 cells, low level expressed in KYSE70 cells and unexpressed in KYSE30, KYSE150, KYSE410, KYSE510, TE13 and BIC1 cells. JAM3 was unmethylated in KYSE450, KYSE520, TE1 and YES2 cells, partial methylated in KYSE70 cells and completely methylated in KYSE30, KYSE150, KYSE410, KYSE510, TE13 and BIC1 cells. The expression of JAM3 is correlated with methylation status. The levels of JAM3 were unchanged in KYSE450, KYSE520, TE1 and YES2 cells, increased in KYSE70 cells and restored expression in KYSE30, KYSE150, KYSE410, KYSE510, TE13 and BIC1 cells after 5-aza-2'-deoxycytidine treatment, suggesting that the expression of JAM3 is regulated by promoter region methylation. JAM3 was methylated in 26.5% (13/49) of EIN and 51.1% (388/760) of primary EC, and methylation of JAM3 was associated significantly with tumor differentiation and family history (all p < 0.05). Methylation of JAM3 is an independent prognostic factor of poor 5-year overall survival (p < 0.05). JAM3 suppresses cell proliferation, colony formation, migration and invasion and induces G1/S arrest and Apoptosis in EC. Further study demonstrated that JAM3 suppressed EC cells and xenograft tumor growth by inhibiting Wnt/β-catenin signaling.

Conclusion: JAM3 is frequently methylated in human EC, and the expression of JAM3 is regulated by promoter region methylation. JAM3 methylation is an early detection and prognostic marker of EC. JAM3 suppresses EC growth both in vitro and in vivo by inhibiting Wnt signaling.

Keywords

DNA methylation; Esophageal cancer; JAM3; Wnt signaling.

Figures
Products